Naitoh J, Witte O, Belldegrun A
Department of Urology, UCLA School of Medicine, Los Angeles, California 90095-1738, USA.
Cancer Res. 1998 Jul 1;58(13):2895-900.
Prostate cancer is the most common solid tumor in American men and is the second most common cause of cancer deaths. Although surgery and radiation therapy are effective for the treatment of organ-confined cancer, there is no effective treatment that is currently available for patients who have metastatic disease. Antiandrogen therapy is only palliative, and chemotherapy has largely been ineffective. However, recent advances in the understanding of the molecular biology of prostate cancer have lead to the development of new treatment strategies for metastatic cancer, including gene-based therapies, immunotherapies, and antiangiogenesis-based therapy. In association with the Jonsson Comprehensive Cancer Center and the University of California, Los Angeles Department of Urology, the Jennifer Jones Simon Foundation assembled 30 of the world's experts in prostate cancer research to review the most recent advances in the study of prostate cancer, with the hope that the resulting discussions would facilitate the rapid translation of new discoveries from the laboratory bench to the clinic.
前列腺癌是美国男性中最常见的实体瘤，也是癌症死亡的第二大常见原因。虽然手术和放射疗法对器官局限性癌症的治疗有效，但目前对于患有转移性疾病的患者尚无有效的治疗方法。抗雄激素疗法只是姑息性的，化疗在很大程度上也无效。然而，最近在前列腺癌分子生物学理解方面的进展已导致转移性癌症新治疗策略的发展，包括基于基因的疗法、免疫疗法和基于抗血管生成的疗法。詹妮弗·琼斯·西蒙基金会与琼森综合癌症中心及加利福尼亚大学洛杉矶分校泌尿外科合作，召集了30位世界前列腺癌研究专家，以回顾前列腺癌研究的最新进展，希望由此产生的讨论能够促进新发现从实验室迅速转化到临床。
